Organ-on-a-chip platforms for studying drug delivery systems

JOURNAL OF CONTROLLED RELEASE

卷:190

Review

Bhise, Nupura S.^1,2  Ribas, Joao^1,2,3,4  Manoharan, Vijayan^1,2  Zhang, Yu Shrike^1,2  Polini, Alessandro^1,2  Massa, Solange^1,2  Dokmeci, Mehmet R.^1,2  Khademhosseini, Ali^1,2,5,6 

[1] Harvard Univ, Sch Med, Brigham & Womens Hosp, Div Biomed Engn,Dept Med, Cambridge, MA 02139 USA

[2] MIT, Harvard Mit Div Hlth Sci & Technol, Cambridge, MA 02139 USA

[3] Univ Coimbra, Inst Interdisciplinary Res, Ctr Neurosci & Cell Biol, Doctoral Programme Expt Biol & Biomed, P-3030789 Coimbra, Portugal

[4] Biocant Biotechnol Innovat Ctr, P-3060197 Cantanhede, Portugal

[5] Harvard Univ, Wyss Inst Biol Inspired Engn, Boston, MA 02115 USA

[6] King Abdulaziz Univ, Dept Phys, Jeddah 21569, Saudi Arabia

关键词: Organ-on-a-chip;    Drug delivery;    Nanoparticle;    Drug screening;    Toxicity;   

DOI  :  10.1016/j.jconrel.2014.05.004

来源: Elsevier

【 摘 要 】

Novel microfluidic tools allow new ways to manufacture and test drug delivery systems. Organ-on-a-chip systems - microscale recapitulations of complex organ functions - promise to improve the drug development pipeline. This review highlights the importance of integrating microfluidic networks with 3D tissue engineered models to create organ-on-a-chip platforms, able to meet the demand of creating robust preclinical screening models. Specific examples are cited to demonstrate the use of these systems for studying the performance of drug delivery vectors and thereby reduce the discrepancies between their performance at preclinical and clinical trials. Wealso highlight the future directions that need to be pursued by the research community for these proof-of-concept studies to achieve the goal of accelerating clinical translation of drug delivery nanoparticles. (C) 2014 Elsevier B. V. All rights reserved.

【 授权许可】

Free